Year in Review: RCC Practice Changing and Practice Informing Trials Updates

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Year in Review: RCC Practice Changing and Practice Informing Trials Updates

By OncoAlert FEATURING Toni Choueiri

275 views

February 20, 2024

Comments 0

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

Feat. R. Alter, R. Shameem

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

RENALC 2024 - Hybrid Global Forum on GU Oncology

Tue, Nov 26, 2024

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

SIR 2023 Conference Coverage

N. Kothary

3.0K views

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

529 views

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

365 views

Opus One: Final Results - RFA in Axial Skeleton

Jason Levy

2.0K views

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

239 views

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

263 views

New

Treatment (De)Intensification in RCC

International Urology Cancer Summit - IUCS

S. Kumar Pal

155 views

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Ph…

Dana-Farber Cancer Institute

B. McGregor

136 views

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very Favo…

2024 ASCO® Annual Meeting Insights Hub

M. Zarba

244 views

Overview of a SoC in 1L mRCC Focusing on the Long-Term Survival Data

David McDermott

247 views

How I Manage Immune Adverse Events in Solid Tumors

Balazs Halmos

1.9K views

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…

2024 ESMO Annual Meeting Insights Hub

C. Porta

175 views

RCC Highlights From ASCO® GU 2024

Dana-Farber Cancer Institute

W. Xu, T. Choueiri

331 views

ASCO® 2024 Insights: "Belzutifan for Advanced Renal Cell Carcinoma"

2024 ASCO® Annual Meeting Insights Hub

E. Jonasch

198 views

ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation …

2024 ESMO Annual Meeting Insights Hub

C. Ciccarese

154 views

1L Treatment Approaches in aRCC: Current Data, Treatment Selection, …

Benjamin Garmezy

251 views

ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC -…

2024 ESMO Annual Meeting Insights Hub

L. Albiges

115 views

AUTOPLAY

Login

Login

Join VuMedi

Year in Review: RCC Practice Changing and Practice Informing Trials Updates

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Recommended

RENALC 2024 - Hybrid Global Forum on GU Oncology

Recent GU Developments and Their Clinical Implications

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Hyperprogression in Cancer Treated With Immunotherapy

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

Opus One: Final Results - RFA in Axial Skeleton

ESMO 2024 Summary: Developmental Therapeutics Highlights

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Treatment (De)Intensification in RCC

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Ph…

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very Favo…

Overview of a SoC in 1L mRCC Focusing on the Long-Term Survival Data

How I Manage Immune Adverse Events in Solid Tumors

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…

RCC Highlights From ASCO® GU 2024

ASCO® 2024 Insights: "Belzutifan for Advanced Renal Cell Carcinoma"

ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation …

1L Treatment Approaches in aRCC: Current Data, Treatment Selection, …

ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC -…